In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

Journal of the National Cancer Institute

Volumn 89, Issue 4, 1997, Pages 293-300

  Correale, Pierpaolo ^a   Walmsley, Konstantin ^b   Nieroda, Carol ^a   Zaremba, Sam ^a   Zhu, Mingzhu ^a   Schlom, Jeffrey ^a,b   Tsang, Kwong Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; HLA A2 ANTIGEN; INTERLEUKIN 2; KALLIKREIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; PEPTIDE SYNTHESIS; PROSTATE CANCER; PROTEIN BINDING; VACCINATION;

EID: 0031033872     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.4.293     Document Type: Article

References (42)

1. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170:797-810.
2. Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol 1991; 146:1692-9.
3. Boon T. Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 1992;58:177-210.
4. Jerome KR, Barnd D, Bendt K, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51:2908-16.
5. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER2/neu protooncogene protein. Cancer Res 1994;54:1071-6.
6. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995;92: 432-6.
7. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
8. Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother 1991;10:153-64.
9. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
10. Darrow TL, Slingluff CL Jr, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 1989;142:3329-35.
11. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91.
12. Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52:6917-25.
13. Fisk B, Chesak B, Ioannides MG, et al. Sequence motifs of human HER-2 proto-oncogene important for peptide binding to HLA-A2. Int J Oncol 1994;5:51-63.
14. Tsang KY, Nicroda CA, DeFilippi R, et al. Induction of human cytotoxic T-cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res 1994;3:183-93.
15. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated oncogene ras proteins. J Exp Med 1991;173:273-6.
16. Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 1993;85:1294-302.
17. Abrams SI, Dobrzanski MJ, Wells DT, Stanziale SF, Zaremba S, Masuelli L, et al. Peptide-specific activation of cytotoxic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol 1995;25:2588-97.
18. Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemens P, van de Velde CJ, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-7.
19. Peace DJ, Xue BH, Sosman JA, Zhang Y. In vitro immunization of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen [abstract]. Cancer Vaccine Symposium 1994, Oct 3-5.
20. Walsh PC. Prostate cancer kills: a strategy to reduce deaths. Urology 1994; 44:463-6.
21. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145: 907-23.
22. Papsidero LD, Kuriyama M, Wang MC, Horoszewicz J, Leong SS, Valenzuela L, et al. Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst 1981;66:37-42.
23. Ioannides CG, Ioannides MG, O'Brien CA. T-cell recognition of oncogene products: a new strategy for immunotherapy. Mol Carcinog 1992;6:77-82.
24. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
25. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
26. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, et al. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
27. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
28. Kast WM, Brandt RM, Drijfhout JW, Melief CJ. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993;14:115-20.
29. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904-12.
30. Anderson KS, Alexander J, Wei M, Cresswell P. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol 1993;151:3407-19.
31. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol 1987;138:1657-9.
32. Boyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in 1g gravity field. Scand J Clin Lab Invest Suppl 1968;97:51-76.
33. Guadagni F, Witt PL, Robbins PF, Schlom J, Greiner JW. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma. Cancer Res 1990;50:6248-55.
34. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993;23: 1215-9.
35. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995;63:231-7.
36. Wang MC, Kuriyama M, Papsidero LD, Loor RM, Valenzuela LA, Murphy GP, et al. Prostate antigen of human cancer patients. In: Busch H, Yeoman LC, editors. Methods in cancer research XIX. New York: Academic Press, 1982;179-97.
37. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280-5.
38. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 1990; 346:574-6.
39. Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 1990;249:1028-30.
40. Weber S, Traunecker A, Finn O, Oliveri F, Gerhard W, Karjalainen K, et al. Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature 1992;356:793-6.
41. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995;375:148-51.
42. Riddell SR, Greenberg PD. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Top Microbiol Immunol 1994;189:9-34.